NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
Clinical Trials
3 trialsNCT02728830 2024-02-21
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Duke University
Phase EARLY_PHASE1 Completed
NCT03694834 2023-11-28
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated